Evaxion Biotech A/S (EVAX) Competitors

Evaxion Biotech A/S (NASDAQ:EVAX) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment.

Does the MarketBeat Community prefer EVAX or LIAN?

Evaxion Biotech A/S received 18 more outperform votes than LianBio when rated by MarketBeat users. Likewise, 62.86% of users gave Evaxion Biotech A/S an outperform vote while only 36.36% of users gave LianBio an outperform vote.

Company	Underperform	Outperform
Evaxion Biotech A/S	Outperform Votes 22 62.86%	Underperform Votes 13 37.14%
LianBio	Outperform Votes 4 36.36%	Underperform Votes 7 63.64%

Do analysts rate EVAX or LIAN?

Evaxion Biotech A/S presently has a consensus price target of $11.00, indicating a potential upside of 272.88%. LianBio has a consensus price target of $5.33, indicating a potential upside of 1,738.45%. Given LianBio's higher probable upside, analysts clearly believe LianBio is more favorable than Evaxion Biotech A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion Biotech A/S	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
LianBio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Do institutionals & insiders hold more shares of EVAX or LIAN?

11.0% of Evaxion Biotech A/S shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 41.6% of Evaxion Biotech A/S shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has more volatility & risk, EVAX or LIAN?

Evaxion Biotech A/S has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500.

Is EVAX or LIAN more profitable?

Evaxion Biotech A/S's return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion Biotech A/S	N/A	N/A	-108.14%
LianBio	N/A	-33.17%	-30.19%

Which has stronger earnings & valuation, EVAX or LIAN?

Evaxion Biotech A/S has higher revenue and earnings than LianBio. Evaxion Biotech A/S is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion Biotech A/S	$278K	57.42	-$22.12M	-$4.33	-0.68
LianBio	N/A	N/A	-$110.29M	-$0.81	-0.36

Does the media prefer EVAX or LIAN?

In the previous week, Evaxion Biotech A/S had 5 more articles in the media than LianBio. MarketBeat recorded 5 mentions for Evaxion Biotech A/S and 0 mentions for LianBio. Evaxion Biotech A/S's average media sentiment score of 0.39 beat LianBio's score of 0.00 indicating that Evaxion Biotech A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Evaxion Biotech A/S	Neutral
LianBio	Neutral

Summary

Evaxion Biotech A/S beats LianBio on 10 of the 16 factors compared between the two stocks.